These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33785131)

  • 1. Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
    Sgambato V
    Prog Brain Res; 2021; 261():265-285. PubMed ID: 33785131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys.
    Millot M; Saga Y; Duperrier S; Météreau E; Beaudoin-Gobert M; Sgambato V
    Neurobiol Dis; 2020 Feb; 134():104643. PubMed ID: 31689516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
    Beaudoin-Gobert M; Epinat J; Météreau E; Duperrier S; Neumane S; Ballanger B; Lavenne F; Liger F; Tourvielle C; Bonnefoi F; Costes N; Bars DL; Broussolle E; Thobois S; Tremblay L; Sgambato-Faure V
    Brain; 2015 Sep; 138(Pt 9):2632-47. PubMed ID: 26117365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
    Beaudoin-Gobert M; Météreau E; Duperrier S; Thobois S; Tremblay L; Sgambato V
    Neuroimage; 2018 Dec; 183():132-141. PubMed ID: 30102999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Météreau E; Beaudoin-Gobert M; Duperrier S; Thobois S; Tremblay L; Sgambato-Faure V
    Mov Disord; 2018 Feb; 33(2):298-309. PubMed ID: 29076602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
    Iravani MM; Jackson MJ; Kuoppamäki M; Smith LA; Jenner P
    J Neurosci; 2003 Oct; 23(27):9107-15. PubMed ID: 14534244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.
    Sgambato V; Tremblay L
    J Neural Transm (Vienna); 2018 Aug; 125(8):1145-1156. PubMed ID: 29502255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
    Lettfuss NY; Fischer K; Sossi V; Pichler BJ; von Ameln-Mayerhofer A
    Neuroimage; 2012 Oct; 63(1):423-33. PubMed ID: 22766162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    J Neurosci; 2011 May; 31(19):7190-8. PubMed ID: 21562283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.
    Maillet A; Krack P; Lhommée E; Météreau E; Klinger H; Favre E; Le Bars D; Schmitt E; Bichon A; Pelissier P; Fraix V; Castrioto A; Sgambato-Faure V; Broussolle E; Tremblay L; Thobois S
    Brain; 2016 Sep; 139(Pt 9):2486-502. PubMed ID: 27538418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice.
    Costa G; Frau L; Wardas J; Pinna A; Plumitallo A; Morelli M
    Mov Disord; 2013 Dec; 28(14):1957-65. PubMed ID: 24108425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Sahin G; Thompson LH; Lavisse S; Ozgur M; Rbah-Vidal L; Dollé F; Hantraye P; Kirik D
    PLoS One; 2014; 9(3):e90759. PubMed ID: 24614598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.
    Ko WK; Li Q; Bezard E
    Neurosci Lett; 2014 Apr; 566():72-6. PubMed ID: 24572591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
    Eskow Jaunarajs KL; George JA; Bishop C
    Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms.
    Ballanger B; Beaudoin-Gobert M; Neumane S; Epinat J; Metereau E; Duperrier S; Broussolle E; Thobois S; Bonnefoi F; Tourvielle C; Lavenne F; Costes N; Lebars D; Zimmer L; Sgambato-Faure V; Tremblay L
    J Neurosci; 2016 Feb; 36(5):1577-89. PubMed ID: 26843639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
    Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.